and rivaroxaban in the remaining trials. In comparisons between rivaroxaban and dabigatran for stroke incidence 16 of 19 (84%) studies showed no difference. Edoxaban was included in only 4 studies overall, without evidence suggestive of differential safety or efficacy compared to other NOACs.

Discussion
The absence of large-scale randomized controlled trials directly comparing individual approved NOAC agents is a notable scientific gap. Studies with non-random treatment allocation provide weak evidence that apixaban is more safe and more effective in stroke prevention when compared to dabigatran and rivaroxaban, while few studies investigated comparison of edoxaban with other NOACs. Future studies should seek to directly compare NOAC agents with each other. For new medications undergoing evaluation for approval, regulatory agencies should consider mandating comparative efficacy and safety testing between medications when one or more medications are already approved for a specific indication.

Introduction
Diabetes mellitus (DM) and heart failure (HF) have substantial overlap in their risk factors, pathophysiology, and increasingly in their management. The DAPA-HF trial showed decreasing rates of cardiovascular death and HF hospitalisation with the use of the sodium-glucose co-transporter 2 inhibitors in patients with HF with reduced ejection fraction (HFrEF). This quality-improvement audit had the dual aims of improving the collection and recording of glycaemic control (HbA1c) while also improving the identification and treatment of diabetes in a HF population.

Methods
In the initial audit, the electronic medical records of 200 consecutive patients of the Heart Failure Unit (HFU) were analysed. Patient demographics and HF classification were recorded alongside the date/result of their most recent HbA1c as logged on the St Michael’s Hospital blood database. The subsequent accuracy and databasing of this data on the bespoke HFU patient system that referred to during every patient interaction was then interrogated with variations in integrity recorded. Our intervention took place at a weekly multidisciplinary meeting where results of the above were presented together with education on the increasing importance of identifying diabetes in HF management. Emphasis was also placed on the need for timely recording of a patient’s recent HbA1c on the HFU patient record system i.e. representing a 34% absolute increase in recording. Importantly, 11 patients identified in the secondary audit were newly diagnosed as diabetics suggesting that these new diagnoses were largely secondary to the increased HbA1c testing that occurred as a result of our intervention.

Summary/Conclusions
We present a completed quality-improvement audit cycle showing a significant increase in HbA1c testing and recording in a busy HF clinic. The data obtained from accurate and consistent HbA1c recording can be used to identify, treat and accurately monitor diabetic control in the HF population.

Background
Left atrial appendage occlusion (LAAO) can be performed in patients with atrial fibrillation with a contraindication to oral anticoagulation to minimise stroke risk. LAAO is usually performed under transoesophageal echocardiography (TOE) guidance. This is labour intensive and requires general anaesthetic (GA). Intracardiac echocardiography (ICE) guided LAAO under conscious sedation may be a safe alternative to TOE guided LAAO. Given the lack of availability of anaesthetic support during the Covid-19 pandemic and the fact that TOE guided LAAO is an aerosol generating procedure, we switched to performing all of our LAAOs under ICE guidance last year. We are the only centre in the country to perform LAAO under ICE guidance. The aim of this retrospective study is to compare the results of ICE guided and TOE guided LAAO procedures.

Methods
We retrospectively analysed all of the medical, procedural and outpatient notes and imaging results of patients who underwent LAAO in our centre between January 2018 and January 2021. The co-primary endpoints were successful implantation of the LAA occlusion device and procedure related mortality. The secondary endpoints were: 1) time spent under fluoroscopy; 2) procedure duration; 3) hospital length of stay; 4) incidence of access site haematomas; 5) incidence of pericardial effusion; 6) incidence of tamponade; 7) device embolisation and 8) peri-device leak on follow up TTE or TOE guided LAAO procedures.

Results
49 patients were admitted to our centre for LAAO occlusion in the study period. They were all included in our study. 12(24.49%) were female. The median age was 78 with an Interquartile Range (IQR) of 10. The most common indication for LAAO occlusion was gastrointestinal bleeding.

Diabetes Mellitus and Heart Failure: A Completed Quality Improvement Audit

Abstracts

56

Diabetes Mellitus and Heart Failure: A Completed Quality Improvement Audit

K Millar, R Gallen, Y Goh, H Muradagha, M McKittrick, T Kiernan, S Arnous. University Hospital Limerick, Limerick, Ireland

Introduction
Diabetes mellitus (DM) and heart failure (HF) have substantial overlap in their risk factors, pathophysiology, and increasing in their management. The DAPA-HF trial showed decreasing rates of cardiovascular death and HF hospitalisation with the use of the sodium-glucose co-transporter 2 inhibitors in patients with HF with reduced ejection fraction (HFrEF). This quality-improvement audit had the dual aims of improving the collection and recording of glycaemic control (HbA1c) while also improving the identification and treatment of diabetes in a HF population.

Methods
In the initial audit, the electronic medical records of 200 consecutive patients of the Heart Failure Unit (HFU) were analysed. Patient demographics and HF classification were recorded alongside the date/result of their most recent HbA1c as logged on the St Michael’s Hospital blood database. The subsequent accuracy and databasing of this data on the bespoke HFU patient system that referred to during every patient interaction was then interrogated with variations in integrity recorded. Our intervention took place at a weekly multidisciplinary meeting where results of the above were presented together with education on the increasing importance of identifying diabetes in HF management. Emphasis was also placed on the need for timely recording of a patient’s recent HbA1c on the HFU patient record system i.e. representing a 34% absolute increase in recording. Importantly, 11 patients identified in the secondary audit were newly diagnosed as diabetics suggesting that these new diagnoses were largely secondary to the increased HbA1c testing that occurred as a result of our intervention.

Summary/Conclusions
We present a completed quality-improvement audit cycle showing a significant increase in HbA1c testing and recording in a busy HF clinic. The data obtained from accurate and consistent HbA1c recording can be used to identify, treat and accurately monitor diabetic control in the HF population.

57

Is Intracardiac Echocardiography Guided Left Atrial Appendage Occlusion a Safe and Cost Effective Alternative to Transoesophageal Echocardiography Guided Left Atrial Appendage Occlusion? A Single Centre Retrospective Review

K Milar, R Gallen, Y Goh, H Muradagha, M McKittrick, T Kiernan, S Arnous. University Hospital Limerick, Limerick, Ireland

Background
Left atrial appendage occlusion (LAAO) can be performed in patients with atrial fibrillation with a contraindication to oral anticoagulation to minimise stroke risk. LAAO is usually performed under transoesophageal echocardiography (TOE) guidance. This is labour intensive and requires general anaesthetic (GA). Intracardiac echocardiography (ICE) guided LAAO under conscious sedation may be a safe alternative to TOE guided LAAO. Given the lack of availability of anaesthetic support during the Covid-19 pandemic and the fact that TOE guided LAAO is an aerosol generating procedure, we switched to performing all of our LAAOs under ICE guidance last year. We are the only centre in the country to perform LAAO under ICE guidance. The aim of this retrospective study is to compare the results of ICE guided and TOE guided LAAO procedures.

Methods
We retrospectively analysed all of the medical, procedural and outpatient notes and imaging results of patients who underwent LAAO in our centre between January 2018 and January 2021. The co-primary endpoints were successful implantation of the LAA occlusion device and procedure related mortality. The secondary endpoints were: 1) time spent under fluoroscopy; 2) procedure duration; 3) hospital length of stay; 4) incidence of access site haematomas; 5) incidence of pericardial effusion; 6) incidence of tamponade; 7) device embolisation and 8) peri-device leak on follow up TTE or ECG Gated CT Aorta [figure 1].

Results
49 patients were admitted to our centre for LAAO occlusion in the study period. They were all included in our study. 12(24.49%) were female. The median age was 78 with an Interquartile Range (IQR) of 10. The most common indication for LAAO occlusion was gastrointestinal bleeding.